The molecular diagnostics firm also received FDA clearance for a strep test and began clinical trials for an E. coli assay in the quarter.
The Group B Strep test is the second test on the firm's menu granted clearance, and is intended for screening pregnant women.
The firm, which went public in October, made a public offering of more than 2.5 million units at $8.80 per unit.
The company is offering about 2.7 million units consisting of preferred stock and warrants at $8.80 per unit.
The increase in C. diff sales resulted from an increase in the number of Great Basin's customers, it said.
The company filed a prospectus to offer units comprising its Series E convertible preferred stock and Series C warrants.
The Salt Lake City-based MDx firm has initiated a clinical trial for its sample-to-result Staph identification/resistance test.
NEW YORK (GenomeWeb News) – Since its founding in 2005, molecular diagnostics firm Great Basin has raised $36 million in private financing, including about $9.6 million in a Series B round completed
NEW YORK (GenomeWeb News) — Great Basin said today that it has secured $9.5 million in Series B funding.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.